Dr. Temel on Anorexia and Cachexia in NSCLC
Jennifer Temel, MD, Associate Professor, Medicine, Harvard Medical School Clinical Director, Thoracic Oncology, Massachusetts General Hospital, and Associate Director, Hematology/Oncology Fellowship Program, Dana-Farber, discusses a phase III study assessing the impact of anamorelin on body weight, lean body mass, and appetite in advanced non-small cell lung cancer (NSCLC) patients with anorexia and cachexia.
Jennifer Temel, MD, Associate Professor, Medicine, Harvard Medical School Clinical Director, Thoracic Oncology, Massachusetts General Hospital, and Associate Director, Hematology/Oncology Fellowship Program, Dana-Farber, discusses a phase III study assessing the impact of anamorelin on body weight, lean body mass, and appetite in advanced non-small cell lung cancer (NSCLC) patients with anorexia and cachexia.
The drug was shown to improve muscle mass and facilitate weight gain in NSCLC patients with anorexia and cachexia, said Temel.
Cancer anorexia and cachexia are common amongst patients with advanced cancer. Currently, therapeutic options are limited, so the potential of anamorelin is exciting, said Temel.
